This study is looking at new therapies for patients with gastrointestinal cancers who have completed their standard treatments. It includes patients with different types of cancers, such as colon, gastric, and pancreatic cancers. The main goal is to see how well the medicines work and if they can help with any remaining cancer cells in the body.
The trial's ID number is NCT05482516. It is a Phase 3 trial, which means it is testing how well the treatment works and how safe it is. The study is FDA-regulated and aims to enroll 20 participants.
Who can join
Adults aged 18 and older can join this study. It is open to both men and women with specific types of gastrointestinal cancers who have completed all their standard treatments. The trial team will confirm who is eligible to participate.
The study team makes the final call on eligibility.
What happens in the study
Everyone in the study will receive two medicines: atezolizumab and bevacizumab. They will get these treatments through an IV on the first day of each 21-day cycle for up to 12 months. There are no separate groups; everyone gets the same treatment.
Where
This trial is running at 3 locations in the United States. All of them are currently recruiting.
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia
Recruiting
John Theurer Cancer Center at Hackensack University Medical Center